K-Group Beta, Inc.

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.
The names of the study drugs involved in this study are:
ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
Gemcitabine (a nucleoside metabolic inhibitor)

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.